Heteroaromatic compounds and their use as dopamine d1 ligands

Abstract

The present invention provides, in part, compounds of formula i: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1 -associated) disorders including, e.G., schizophrenia (e.G., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.G., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, parkinson's disease, anxiety, and depression.